147 related articles for article (PubMed ID: 35507442)
1. Serum Neurofilament Light Chain in Wilson's Disease: A Promising Indicator but Unparallel to Real-Time Treatment Response.
Wang RM; Xu WQ; Zheng ZW; Yang GM; Zhang MY; Ke HZ; Xia N; Dong Y; Wu ZY
Mov Disord; 2022 Jul; 37(7):1531-1535. PubMed ID: 35507442
[TBL] [Abstract][Full Text] [Related]
2. Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations.
Ziemssen T; Akgun K; Członkowska A; Antos A; Bembenek J; Kurkowska-Jastrzębska I; Przybyłkowski A; Skowrońska M; Smolinski L; Litwin T
Mov Disord; 2022 May; 37(5):1074-1079. PubMed ID: 35114010
[TBL] [Abstract][Full Text] [Related]
3. Serum neurofilament light chain and initial severity of neurological disease predict the early neurological deterioration in Wilson's disease.
Ziemssen T; Smolinski L; Członkowska A; Akgun K; Antos A; Bembenek J; Kurkowska-Jastrzębska I; Przybyłkowski A; Skowrońska M; Redzia-Ogrodnik B; Litwin T
Acta Neurol Belg; 2023 Jun; 123(3):917-925. PubMed ID: 36098934
[TBL] [Abstract][Full Text] [Related]
4. Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease.
Shribman S; Heller C; Burrows M; Heslegrave A; Swift I; Foiani MS; Gillett GT; Tsochatzis EA; Rowe JB; Gerhard A; Butler CR; Masellis M; Bremner F; Martin A; Jung L; Cook P; Zetterberg H; Bandmann O; Rohrer JD; Warner TT
Mov Disord; 2021 Feb; 36(2):503-508. PubMed ID: 33078859
[TBL] [Abstract][Full Text] [Related]
5. Plasma neurofilament light chain as a biomarker in Wilson's disease.
Yang J; Huang Z; Yang H; Luo Y; You H; Chen D; Pei Z; Li X
Parkinsonism Relat Disord; 2022 Feb; 95():5-10. PubMed ID: 34942565
[TBL] [Abstract][Full Text] [Related]
6. Comparative assessment of clinical rating scales in Wilson's disease.
Volpert HM; Pfeiffenberger J; Gröner JB; Stremmel W; Gotthardt DN; Schäfer M; Weiss KH; Weiler M
BMC Neurol; 2017 Jul; 17(1):140. PubMed ID: 28732478
[TBL] [Abstract][Full Text] [Related]
7. Brain magnetic resonance imaging and severity of neurological disease in Wilson's disease - the neuroradiological correlations.
Rędzia-Ogrodnik B; Członkowska A; Bembenek J; Antos A; Kurkowska-Jastrzębska I; Skowrońska M; Smoliński Ł; Litwin T
Neurol Sci; 2022 Jul; 43(7):4405-4412. PubMed ID: 35275318
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of neurological Wilson's disease with corpus callosum abnormalities.
Zhou ZH; Wu YF; Cao J; Hu JY; Han YZ; Hong MF; Wang GQ; Liu SH; Wang XM
BMC Neurol; 2019 May; 19(1):85. PubMed ID: 31053106
[TBL] [Abstract][Full Text] [Related]
9. Unified Wilson's Disease Rating Scale - a proposal for the neurological scoring of Wilson's disease patients.
Członkowska A; Tarnacka B; Möller JC; Leinweber B; Bandmann O; Woimant F; Oertel WH
Neurol Neurochir Pol; 2007; 41(1):1-12. PubMed ID: 17330175
[TBL] [Abstract][Full Text] [Related]
10. Brain Atrophy Is Substantially Accelerated in Neurological Wilson's Disease: A Longitudinal Study.
Smolinski L; Ziemssen T; Akgun K; Antos A; Skowrońska M; Kurkowska-Jastrzębska I; Członkowska A; Litwin T
Mov Disord; 2022 Dec; 37(12):2446-2451. PubMed ID: 36165286
[TBL] [Abstract][Full Text] [Related]
11. Subclinical neurological involvement does not develop if Wilson's disease is treated early.
Dubbioso R; Ranucci G; Esposito M; Di Dato F; Topa A; Quarantelli M; Matarazzo M; Santoro L; Manganelli F; Iorio R
Parkinsonism Relat Disord; 2016 Mar; 24():15-9. PubMed ID: 26851839
[TBL] [Abstract][Full Text] [Related]
12. Neuroimaging Correlates of Cognitive Deficits in Wilson's Disease.
Shribman S; Burrows M; Convery R; Bocchetta M; Sudre CH; Acosta-Cabronero J; Thomas DL; Gillett GT; Tsochatzis EA; Bandmann O; Rohrer JD; Warner TT
Mov Disord; 2022 Aug; 37(8):1728-1738. PubMed ID: 35723521
[TBL] [Abstract][Full Text] [Related]
13. Application Value of Serum Neurofilament Light Protein for Disease Staging in Huntington's Disease.
Li XY; Bao YF; Xie JJ; Gao B; Qian SX; Dong Y; Wu ZY
Mov Disord; 2023 Jul; 38(7):1307-1315. PubMed ID: 37148558
[TBL] [Abstract][Full Text] [Related]
14. Free water imaging as a novel biomarker in Wilson's disease: A cross-sectional study.
Jing XZ; Li GY; Wu YP; Yuan XZ; Luo XG; Chen JL; Taximaimaiti R; Wang XP; Li JQ
Parkinsonism Relat Disord; 2023 Jan; 106():105234. PubMed ID: 36481719
[TBL] [Abstract][Full Text] [Related]
15. Impact of treatment on blood-brain barrier impairment in Wilson's disease.
Misztal M; Członkowska A; Cudna A; Palejko A; Litwin T; Piechal A; Kurkowska-Jastrzębska I
Neurol Neurochir Pol; 2023; 57(4):379-386. PubMed ID: 37526174
[TBL] [Abstract][Full Text] [Related]
16. Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin-related amyloidosis-A Swiss reference center experience.
Loser V; Benkert P; Vicino A; Lim Dubois Ferriere P; Kuntzer T; Pasquier J; Maceski A; Kuhle J; Theaudin M
J Peripher Nerv Syst; 2023 Mar; 28(1):86-97. PubMed ID: 36471582
[TBL] [Abstract][Full Text] [Related]
17. Serum pentraxin 3 is elevated in patients with neurological Wilson's disease.
Wang H; Cheng N; Dong J; Wang X; Han Y; Yang R; Han Y
Clin Chim Acta; 2016 Nov; 462():178-182. PubMed ID: 27553858
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of patients with neurological form of Wilson's disease compliant to the de-coppering treatment.
Stanković I; Jovanović Č; Vitković J; Svetel M; Pekmezović T; Tomić A; Kresojević N; Marković V; Ječmenica Lukić M; Petrović I; Dragašević-Mišković N; Kostić V
J Neurol; 2023 Jul; 270(7):3492-3498. PubMed ID: 37016067
[TBL] [Abstract][Full Text] [Related]
19. Wilson's disease: update on pathogenesis, biomarkers and treatments.
Shribman S; Poujois A; Bandmann O; Czlonkowska A; Warner TT
J Neurol Neurosurg Psychiatry; 2021 Oct; 92(10):1053-1061. PubMed ID: 34341141
[TBL] [Abstract][Full Text] [Related]
20. Serum neurofilament light chain levels in Covid-19 patients without major neurological manifestations.
Verde F; Milone I; Bulgarelli I; Peverelli S; Colombrita C; Maranzano A; Calcagno N; Ticozzi N; Perego GB; Parati G; Torresani E; Ratti A; Silani V
J Neurol; 2022 Nov; 269(11):5691-5701. PubMed ID: 35781535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
